Trump nominates White House aide Heidi Overton to lead Food and Drug Administration
President Donald Trump has chosen White House domestic policy adviser Heidi Overton to lead the Food and Drug Administration, filling a vacancy left by Marty Makary in May.
Nomination and background
President Donald Trump nominated White House domestic policy adviser Dr. Heidi Overton to serve as commissioner of the Food and Drug Administration on 19 August 2026. Overton is a 37-year-old physician board-certified in public health and general preventive medicine, holding a medical degree from the University of New Mexico and a doctorate in clinical investigation from Johns Hopkins University. She previously served as chief policy officer at the America First Policy Institute and was a White House fellow between 2019 and 2020. The nomination fills the post vacated by Dr. Marty Makary, who resigned in May 2026 following policy disagreements regarding flavored vapes. Overton was selected after the administration previously considered acting commissioner Kyle Diamantas and former Republican representative Brad Wenstrup.
- Overton serves as White House fellow during Johns Hopkins medical residency
- Overton publishes policy brief at America First Policy Institute targeting mifepristone
- Overton participates in White House meeting on glyphosate production
- FDA Commissioner Marty Makary resigns over flavored vape policies
- President Donald Trump nominates Overton to lead the FDA
Policy stances and vaccine orders
Overton has played a central role in shaping health directives under the Make America Healthy Again initiative. She recently appeared alongside Trump during an Oval Office announcement promoting an executive order to separate the measles, mumps, and rubella vaccine into three individual shots. At that event, Overton urged state health departments to align with the new federal guidance, while the American Academy of Pediatrics described the order as dangerous during an ongoing measles outbreak. On reproductive health, Overton authored a 2023 policy brief characterizing the abortion pill mifepristone as teleabortion and advocating for tighter federal restrictions on its distribution.
We do still recommend the measles vaccine for all children, but we want parents to be informed about the timing and to have the option to separate them out.
Pushback from lawmakers and activists
The selection met immediate skepticism in the Senate, where Overton must secure approval from the Committee on Health, Education, Labor, and Pensions before advancing to a full floor vote. Committee chairman Bill Cassidy, a physician and Republican senator from Louisiana, stated that Overton's backing of the vaccine executive order called her scientific judgment into doubt.
Dr. Overton's active role in last week's nonsensical vaccine executive order calls into question her commitment to standing up for sound science and protecting children's health. That alone is almost disqualifying.
Opposition also surfaced within segments of the Make America Healthy Again movement over chemical safety. Environmental activist Kelly Ryerson criticized Overton for defending administration decisions that expanded manufacturing protections for Bayer's weedkiller glyphosate during an April 2026 White House meeting.
When I was at the White House MAHA meeting, Overton delivered all of Bayer's talking points.
Administration defense and confirmation outlook
The White House defended Overton's qualifications following the announcement. White House spokesman Kush Desai stated that Overton had spent eighteen months coordinating policy across the Department of Health and Human Services, the FDA, the Centers for Disease Control and Prevention, and the Department of Agriculture. Chris Meekins, a health analyst at Raymond James and former department official, questioned her administrative readiness, noting her transition into national policy occurred during her surgical residency. The Senate remains in recess until mid-September 2026, and Cassidy has not yet scheduled a confirmation hearing.
